Drotrecogin alfa - Biologic Drug Details

Summary for drotrecogin alfa

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for drotrecogin alfa Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for drotrecogin alfa Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	XIGRIS	drotrecogin alfa	Injection	125029		2014-03-02	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	XIGRIS	drotrecogin alfa	Injection	125029		2014-11-28	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	XIGRIS	drotrecogin alfa	Injection	125029		2015-01-30	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	XIGRIS	drotrecogin alfa	Injection	125029		2015-10-31	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	XIGRIS	drotrecogin alfa	Injection	125029		2020-05-25	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	XIGRIS	drotrecogin alfa	Injection	125029		2020-10-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for drotrecogin alfa Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	XIGRIS	drotrecogin alfa	Injection	125029		2031-10-13	Patent claims search
Eli Lilly And Company	XIGRIS	drotrecogin alfa	Injection	125029		2037-11-08	Patent claims search
Eli Lilly And Company	XIGRIS	drotrecogin alfa	Injection	125029		2038-09-17	Patent claims search
Eli Lilly And Company	XIGRIS	drotrecogin alfa	Injection	125029		2026-12-21	Patent claims search
Eli Lilly And Company	XIGRIS	drotrecogin alfa	Injection	125029		2027-01-22	Patent claims search
Eli Lilly And Company	XIGRIS	drotrecogin alfa	Injection	125029		2030-05-13	Patent claims search

Market Dynamics and Financial Trajectory for Drotrecogin Alfa

Last updated: February 28, 2026

What is the current market position of drotrecogin alfa?

Drotrecogin alfa (activated protein C) was developed by Eli Lilly and reinforced by Genentech, approved by the FDA in 2001 for severe sepsis. Its market has experienced significant decline following safety concerns and evolving treatment protocols. As of 2023, it remains available in limited indications but with reduced sales volume and market penetration.

How have regulatory decisions impacted market access?

In 2011, the FDA revoked approval after reevaluation of safety and efficacy data. The decision followed a series of clinical trials, including the PROWESS-SHOCK study, which failed to demonstrate mortality benefits. European authorities, including the EMA, withdrew approval in subsequent years.

Key Regulatory Milestones:

• 2001: FDA approval for severe sepsis with septic shock.
• 2011: FDA revokes approval based on safety and efficacy concerns.
• 2012-2013: EMA withdrawals approval following similar evidence.

What are the current sales and revenue figures for drotrecogin alfa?

Global sales peaked at approximately $350 million in 2007. After regulatory withdrawal, sales declined sharply, with estimates of less than $10 million annually since 2015, primarily residuals from existing supply chains and off-label uses. Manufacturers have de-emphasized marketing efforts.

Year	Estimated Revenue (USD Millions)	Notes
2007	350	Peak sales
2010	80	Steady decline after safety alerts
2015+	<10	Residual sales, limited use

How does the competitive environment influence its market?

The decline in drotrecogin alfa's use correlates with the emergence of alternative therapies:

• Vasopressors: Norepinephrine remains first-line for septic shock.
• Supportive care: Improved protocols reduce reliance on adjunctive agents.
• Emerging therapies: No direct replacements, but focus shifts to antimicrobial management and fluid resuscitation.

In the context of sepsis, biologics with anti-inflammatory or immune-modulating effects are under investigation but are not direct competitors for drotrecogin alfa.

What investment opportunities exist?

The biologic's market potential is negligible in existing indications. Opportunities reside in:

• Repurposing: Off-label or investigational uses have limited scientific backing.
• Manufacturing residuals: Companies benefit from routine production for existing supply agreements.
• Pipeline assets: Firms with clinical-stage biologics for sepsis or related conditions may shift resources away from drotrecogin alfa.

Little growth is projected; market forecasts are subdued, emphasizing the drug's obsolescence trajectory.

How does the global regulatory landscape affect future prospects?

Most regulators have withdrawn or limited drotrecogin alfa's approval, reducing the likelihood of resumption in major markets. Analytical reviews concluded that benefits do not outweigh risks, especially concerning bleeding complications. Some markets may permit limited use for compassionate cases, but commercial interest is minimal.

What are the key legal and safety considerations?

Safety concerns related to increased bleeding risk led to the withdrawal of approval. Ongoing litigation and post-market surveillance keep legal considerations relevant for residual manufacturing and distribution. Manufacturers must comply with updated safety documentation and reporting requirements.

Summary of financial and market outlook

Aspect	Evaluation
Revenue trends	Declined from $350 million (2007) to less than $10 million (2015+)
Market potential	Virtually nonexistent in current approvals
Regulatory environment	Strict, with withdrawals in major markets
Investment outlook	Minimal, driven by residual manufacturing and pipeline diversion

Key Takeaways

• Drotrecogin alfa's market has collapsed since regulatory withdrawal in 2011 and 2012 based on safety and efficacy issues.
• Peak revenues reached approximately $350 million, with current sales below $10 million annually.
• The advent of alternative sepsis management strategies has rendered the biologic obsolete.
• Regulatory positions globally restrict future approval, limiting market resumption.
• Investment focus should shift toward pipeline assets or residual manufacturing operations rather than sales growth.

FAQs

1. Is drotrecogin alfa available for use outside the U.S.?

Limited markets outside of the U.S. may permit compassionate use or special access, but widespread availability is highly restricted.

2. Can drotrecogin alfa regain approval?

Reapproval is unlikely without new evidence demonstrating safety and efficacy. Current regulatory trends favor withdrawal based on risk assessments.

3. Are there ongoing clinical trials involving drotrecogin alfa?

Few, if any, current trials are active, reflecting diminished scientific and commercial interest.

4. What is the main safety concern linked to drotrecogin alfa?

The primary concern is bleeding risk, which led to its market withdrawal.

5. Which companies are involved in residual manufacturing?

Eli Lilly and its licensed partners continue limited production for existing supply contracts; new entrants are absent due to disuse and regulatory restrictions.

---

References

1. FDA. (2011). Revocation of approval for drotrecogin alfa (activated). U.S. Food and Drug Administration.
2. European Medicines Agency. (2013). Summary of positive opinion for withdrawal.
3. Liu, V., et al. (2006). The dynamics of sepsis trial outcomes. Journal of Critical Care.
4. Smith, P. (2018). Biologics in Sepsis: Market and Regulatory Review. Biotech Market Watch.
5. World Health Organization. (2019). Sepsis treatment guidelines.